Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine
Advances in Drug and Alcohol Research · 2021
DOI: 10.3389/adar.2021.10009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Drug and Alcohol Research, 2021. Verfasst von Courtney M Cameron und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Death by suicide is a global epidemic with over 800 K suicidal deaths worlwide in 2012. Suicide is the 10th leading cause of death among Americans and more than 44 K people died by suicide in 2019 in the United States. Patients with chronic pain, including, but not limited to, those with substance use disorders, are particularly vulnerable. Chronic pain patients have twice the risk of death by suicide compared to those without pain, and 50% of chronic pain patients report that they have considered suicide at some point due to their pain. The kappa opioid system is implicated in negative mood states including dysphoria, depression, and anxiety, and recent evidence shows that chronic pain increases the function of this system in limbic brain regions important for affect and motivation. Additionally, dynorphin, the endogenous ligand that activates the kappa opioid receptor is increased in the caudate putamen of human suicide victims. A potential treatment for reducing suicidal ideation and suicidal attempts is buprenorphine. Buprenorphine, a partial mu opioid agonist with kappa opioid antagonist properties, reduced suicidal ideation in chronic pain patients with and without an opioid use disorder. This review will highlight the clinical and preclinical evidence to support the use of buprenorphine in mitigating pain-induced negative affective states and suicidal thoughts, where these effects are at least partially mediated via its kappa antagonist properties.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States.
- Shirley and Stefan Hatos Center for Neuropharmacology, University of California, Los Angeles, Los Angeles, CA, United States.
- Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, United States.
- David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
- Department of Psychology, University of California, Los Angeles, Los Angeles, CA, United States.
Förderung
- NIDA NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Cameron, C. M., Nieto, S., Bosler, L., Wong, M., Bishop, I., Mooney, L., & Cahill, C. M. (2021). Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. Advances in Drug and Alcohol Research. https://doi.org/10.3389/adar.2021.10009
Vancouver
Cameron CM, Nieto S, Bosler L, Wong M, Bishop I, Mooney L, et al. Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine. Advances in Drug and Alcohol Research. 2021. doi:10.3389/adar.2021.10009
BibTeX
@article{Cameron2021,
author = {Cameron, Courtney M and Nieto, Steven and Bosler, Lucienne and Wong, Megan and Bishop, Isabel and Mooney, Larissa and Cahill, Catherine M},
title = {Mechanisms Underlying the Anti-Suicidal Treatment Potential of Buprenorphine},
journal = {Advances in Drug and Alcohol Research},
year = {2021},
doi = {10.3389/adar.2021.10009}
}
EUVIMED